Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.86B | $5.87B | $5.15B | $6.56B | $8.50B | $16.1B | $12.2B | $13.1B | $14.2B | $14.3B |
| Revenue growth | — | 20.8% | -12.4% | 27.4% | 29.6% | 89.1% | -24.3% | 7.8% | 8.3% | 1.0% |
| Operating income | $1.33B | $2.08B | $2.53B | $2.21B | $3.58B | $8.95B | $4.74B | $4.05B | $3.99B | $3.58B |
| Operating margin | 27.4% | 35.4% | 49.3% | 33.7% | 42.1% | 55.7% | 38.9% | 30.9% | 28.1% | 24.9% |
| Net income | $896M | $1.20B | $2.44B | $2.12B | $3.51B | $8.08B | $4.34B | $3.95B | $4.41B | $4.50B |
| Net margin | 18.4% | 20.4% | 47.5% | 32.3% | 41.3% | 50.2% | 35.6% | 30.1% | 31.1% | 31.4% |
| EPS (diluted) | $7.70 | $10.34 | $21.29 | $18.46 | $30.52 | $71.97 | $38.22 | $34.77 | $38.34 | $41.48 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.49B | $1.31B | $2.20B | $2.43B | $2.62B | $7.08B | $5.01B | $4.59B | $4.42B | $4.98B |
| Capital expenditures | $512M | $273M | $383M | $430M | $615M | $552M | $590M | $719M | $756M | $898M |
| Free cash flow | $974M | $1.03B | $1.81B | $2.00B | $2.00B | $6.53B | $4.42B | $3.88B | $3.66B | $4.08B |
| Share buybacks | $0.00 | $0.00 | $4.40M | $276M | $5.85B | $1.65B | $2.08B | $2.23B | $2.60B | $3.44B |
| Dividends paid | — | — | — | — | — | — | — | $0.00 | $0.00 | $370M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $535M | $813M | $1.47B | $1.62B | $2.19B | $2.89B | $3.11B | $2.73B | $2.49B | $3.12B |
| Total assets | $6.97B | $8.76B | $11.7B | $14.8B | $17.2B | $25.4B | $29.2B | $33.1B | $37.8B | $40.6B |
| Total liabilities | $2.52B | $2.62B | $2.98B | $3.72B | $6.14B | $6.67B | $6.55B | $7.11B | $8.41B | $9.30B |
| Long-term debt | — | — | — | $0.00 | $1.98B | $1.98B | $1.98B | $1.98B | $1.98B | $1.99B |
| Shareholders' equity | $4.45B | $6.14B | $8.76B | $11.1B | $11.0B | $18.8B | $22.7B | $26.0B | $29.4B | $31.3B |
| Retained earnings | $1.75B | $2.95B | $5.25B | $7.38B | $10.9B | $19.0B | $23.3B | $27.3B | $31.7B | $35.8B |
| Shares (wtd avg diluted) | 116M | 116M | 115M | 115M | 115M | 112M | 114M | 114M | 115M | 109M |
Every figure is extracted from REGENERON PHARMACEUTICALS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.